Approaches and Challenges in SARS-CoV-2 Vaccine Development
- 10 August 2020
- journal article
- review article
- Published by Elsevier BV in Cell Host & Microbe
- Vol. 28 (3), 364-370
- https://doi.org/10.1016/j.chom.2020.08.002
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- Bill and Melinda Gates Foundation
This publication has 89 references indexed in Scilit:
- Anti-Severe Acute Respiratory Syndrome Coronavirus Spike Antibodies Trigger Infection of Human Immune Cells via a pH- and Cysteine Protease-Independent FcγR PathwayJournal of Virology, 2011
- T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected MiceJournal of Virology, 2010
- A Novel Replication-Competent Vaccinia Vector MVTT Is Superior to MVA for Inducing High Levels of Neutralizing Antibody via Mucosal VaccinationPLOS ONE, 2009
- Vaccines to prevent severe acute respiratory syndrome coronavirus-induced diseaseVirus Research, 2008
- Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory SyndromeJournal of Virology, 2007
- Vaccine Efficacy in Senescent Mice Challenged with Recombinant SARS-CoV Bearing Epidemic and Zoonotic Spike VariantsPLoS Medicine, 2006
- Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike VariantsJournal of Virology, 2005
- Expression of SARS-coronavirus nucleocapsid protein in Escherichia coli and Lactococcus lactis for serodiagnosis and mucosal vaccinationApplied Microbiology and Biotechnology, 2005
- A DNA vaccine induces SARS coronavirus neutralization and protective immunity in miceNature, 2004
- Effects of a "new" human respiratory virus in volunteers.BMJ, 1967